Motor Cortex is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The motor [cortex[/brain-regions/cortex is a collective term for several frontal lobe regions that are directly involved in the planning, control, and execution of voluntary movements. The primary motor [cortex[/brain-regions/cortex (M1, Brodmann area 4) occupies the precentral gyrus, immediately anterior to the central sulcus, and is the principal source of descending corticospinal projections that drive voluntary movement (Penfield & Boldrey, 1937). Together with the premotor [cortex[/brain-regions/cortex (Brodmann area 6) and the supplementary motor area (SMA), the motor [cortex[/brain-regions/cortex forms a hierarchical motor system that integrates sensory information, motor planning, and execution signals. Degeneration of motor [cortex[/brain-regions/cortex [neurons[/entities/neurons — particularly the giant Betz cells of layer V — is a defining feature of [amyotrophic lateral sclerosis[/diseases/als (ALS) and is prominent in [corticobasal degeneration[/diseases/corticobasal-degeneration, [progressive supranuclear palsy[/diseases/psp, and [primary lateral sclerosis[/diseases/primary-lateral-sclerosis (Eisen et al., 2017).
¶ Anatomy and Organization
¶ Location and Gross Structure
The primary motor [cortex[/brain-regions/cortex occupies the posterior portion of the frontal lobe along the precentral gyrus, extending from the lateral (Sylvian) fissure inferiorly to the longitudinal fissure superiorly, where it continues onto the medial surface of the hemisphere (Geyer et al., 1996). M1 is bordered posteriorly by the primary somatosensory [cortex[/brain-regions/cortex (Brodmann areas 3, 1, 2) across the central sulcus, and anteriorly by the premotor [cortex[/brain-regions/cortex (area 6). It receives extensive inputs from the [thalamus[/brain-regions/thalamus (ventral lateral nucleus), [basal ganglia[/brain-regions/basal-ganglia circuits, the [cerebellum[/brain-regions/cerebellum (via the thalamus), and the [prefrontal cortex[/brain-regions/prefrontal-cortex.
The primary motor [cortex[/brain-regions/cortex is classified as agranular [cortex[/brain-regions/cortex because it lacks a well-defined internal granular layer (layer IV), a feature that distinguishes it from sensory cortices (Brodmann, 1909). Its cytoarchitecture is characterized by:
- Layer I (molecular layer): Sparse [neurons[/entities/neurons with primarily apical dendrites and axonal processes
- Layer II/III (external pyramidal layers): Medium-sized pyramidal [neurons[/entities/neurons that participate in intracortical and corticocortical circuits
- Layer V (internal pyramidal layer): The defining feature — containing the Betz cells, giant pyramidal [neurons[/entities/neurons measuring 60–100 μm in soma diameter, the largest [neurons[/entities/neurons in the human [cortex[/brain-regions/cortex (Rivara et al., 2003). These cells give rise to the corticospinal and corticobulbar tracts
- Layer VI (multiform layer): Polymorphic [neurons[/entities/neurons projecting mainly to the [thalamus[/brain-regions/thalamus
Betz cells are giant pyramidal [neurons[/entities/neurons unique to layer V of the primary motor [cortex[/brain-regions/cortex. First described by Vladimir Betz in 1874, they are the largest [neurons[/entities/neurons in the central nervous system, with soma diameters reaching up to 100 μm and axon lengths extending the full length of the [spinal cord[/brain-regions/spinal-cord (Lemon, 2008). Key features of Betz cells include:
- Circumferential basal dendrites that extend in all directions, unlike the more oriented dendrites of smaller pyramidal cells
- Rapid conduction velocities (50–70 m/s) due to heavily myelinated, large-caliber axons
- Monosynaptic connections to spinal motor [neurons[/entities/neurons — the corticomotoneuronal system — enabling fine manual dexterity (Lemon, 2008)
- Accumulation of neuromelanin and lipofuscin with aging (Braak & Braak, 1976)
- Estimated population: Approximately 30,000–40,000 Betz cells per hemisphere in humans, representing only ~10% of corticospinal tract [neurons[/entities/neurons but contributing the largest-caliber axons
The primary motor [cortex[/brain-regions/cortex exhibits a systematic somatotopic map — the motor homunculus — first mapped by Wilder Penfield using direct electrical stimulation during neurosurgery (Penfield & Boldrey, 1937). The body is represented in an inverted orientation:
- Medial surface: Leg and foot (extending into the paracentral lobule)
- Dorsolateral convexity (superior): Trunk and arm
- Dorsolateral convexity (inferior): Hand, face, tongue, and larynx
- The representation is disproportionate — the hand and face occupy the largest cortical territory, reflecting the density of fine motor control in these regions
Beyond M1, the broader motor [cortex[/brain-regions/cortex includes:
- Premotor [cortex[/brain-regions/cortex (PMC, area 6 lateral): Involved in motor planning, especially for externally guided movements. Contains mirror [neurons[/entities/neurons in primates (Rizzolatti & Craighero, 2004)
- Supplementary motor area (SMA, area 6 medial): Critical for internally generated movement sequences, bimanual coordination, and speech motor control (Nachev et al., 2008)
- Cingulate motor areas: Located in the [cingulate cortex[/brain-regions/cingulate-cortex sulcal depths, involved in motivational and emotional aspects of motor behavior
¶ Neurochemistry and Neurotransmission
The motor [cortex[/brain-regions/cortex relies on several neurotransmitter systems:
- Glutamate: The primary excitatory neurotransmitter of pyramidal [neurons[/entities/neurons, including Betz cells, which form glutamatergic corticospinal projections
- GABA: Inhibitory interneurons (particularly [parvalbumin-positive[/cell-types/pv-interneurons and [somatostatin-positive[/cell-types/sst-interneurons subtypes) regulate motor [cortex[/brain-regions/cortex excitability and shape motor output timing
- [dopamine[/entities/dopamine: Modulatory input from the [substantia nigra[/brain-regions/substantia-nigra pars compacta and ventral tegmental area influences motor [cortex[/brain-regions/cortex excitability and plasticity
- [acetylcholine[/entities/acetylcholine: Cholinergic projections from the [nucleus basalis of Meynert[/brain-regions/nucleus-basalis-of-meynert modulate cortical plasticity and motor learning
- Serotonin: Raphe nucleus projections modulate motor [cortex[/brain-regions/cortex excitability
[ALS[/diseases/als is the prototypical motor [cortex[/brain-regions/cortex neurodegenerative disease, characterized by the progressive loss of both upper motor [neurons[/entities/neurons (UMNs) in the primary motor [cortex[/brain-regions/cortex and lower motor [neurons[/entities/neurons in the [brainstem[/brain-regions/brainstem and [spinal cord[/brain-regions/spinal-cord (Hardiman et al., 2017). Motor [cortex[/brain-regions/cortex pathology in ALS includes:
- Betz cell degeneration: Loss of Betz cells and large layer V pyramidal [neurons[/entities/neurons is a hallmark finding. Studies show 50–70% Betz cell loss in ALS patients (Hammer et al., 1979)
- Corticospinal tract degeneration: Wallerian degeneration of the descending pyramidal tract, visible as myelin pallor from the internal capsule through the cerebral peduncles to the lateral corticospinal tracts
- [TDP-43[/proteins/tdp-43 inclusions: Cytoplasmic inclusions of phosphorylated [TDP-43[/proteins/tdp-43 in remaining layer V [neurons[/entities/neurons, the pathological hallmark of most ALS cases (Neumann et al., 2006)
- Cortical hyperexcitability: Transcranial magnetic stimulation (TMS) studies reveal early motor [cortex[/brain-regions/cortex hyperexcitability, with reduced short-interval intracortical inhibition (SICI), suggesting [excitotoxicity[/entities/excitotoxicity plays a role in disease pathogenesis (Vucic et al., 2008)
- [FUS[/proteins/fus-protein and [SOD1[/proteins/sod1-protein mutations also cause UMN-predominant motor [cortex[/brain-regions/cortex degeneration in familial ALS
The "dying forward" hypothesis proposes that motor [cortex[/brain-regions/cortex hyperexcitability and glutamatergic excitotoxicity drive anterograde degeneration of lower motor [neurons[/entities/neurons via corticomotoneuronal projections (Eisen et al., 2017).
[corticobasal degeneration[/diseases/corticobasal-degeneration is a 4-repeat [tauopathy[/mechanisms/tauopathy characterized by asymmetric cortical atrophy, often centered on the motor and premotor [cortex[/brain-regions/cortex and [basal ganglia[/brain-regions/basal-ganglia (Armstrong et al., 2013). Motor cortex pathology includes:
- Ballooned (achromatic) [neurons[/entities/neurons in layers III and V
- Astrocytic plaques — distinctive tau[/proteins/tau-protein-positive glial inclusions
- Cortical atrophy predominantly affecting the perirolandic region (motor and sensory cortex), SMA, and superior frontal gyrus
- Clinically manifests as progressive asymmetric limb rigidity, apraxia, alien limb phenomenon, and cortical sensory loss
[PSP[/diseases/psp involves tau[/proteins/tau-protein pathology in both subcortical and cortical structures, with the motor cortex and SMA affected in later stages (Dickson et al., 2007). [Tau[/entities/tau-protein-positive tufted [astrocytes[/cell-types/astrocytes and neurofibrillary tangles accumulate in the motor cortex, contributing to upper motor neuron signs.
[PLS] is a pure UMN syndrome with selective degeneration of Betz cells and corticospinal [neurons[/entities/neurons without lower motor neuron involvement (Singer et al., 2007). Severe loss of Betz cells with gliosis and corticospinal tract degeneration are the pathological hallmarks, often with [TDP-43[/proteins/tdp-43 pathology similar to ALS.
While [Alzheimer's disease[/diseases/alzheimers preferentially affects the [entorhinal cortex[/brain-regions/entorhinal-cortex and [hippocampus[/brain-regions/hippocampus, the primary motor cortex is relatively spared until late stages (Braak stage V-VI) (Braak & Braak, 1991). [Amyloid-Beta[/proteins/Amyloid-Beta plaques and tau[/proteins/tau-protein tangles eventually accumulate in the motor cortex, but the relative preservation of M1 until late disease contrasts with the early vulnerability of limbic and association cortices.
The motor cortex — specifically the Betz cells — exhibits remarkable [selective neuronal vulnerability[/mechanisms/selective-neuronal-vulnerability in motor neuron diseases. Factors contributing to this vulnerability include:
- Extreme soma size and axon length: Betz cells maintain axons up to 1 meter long, imposing enormous metabolic and transport demands (Brownell et al., 1970)
- High metabolic rate: Continuous pacemaking activity requires sustained energy production, making these [neurons[/entities/neurons sensitive to [mitochondrial dysfunction[/mechanisms/mitochondrial-dysfunction
- Glutamate excitotoxicity: Betz cells receive dense glutamatergic inputs and express high levels of AMPA receptors, predisposing them to [excitotoxicity[/entities/excitotoxicity
- Limited calcium buffering: Compared to resistant interneuron populations, Betz cells have lower expression of calcium-binding proteins (calbindin, parvalbumin)
- [oxidative stress[/mechanisms/oxidative-stress sensitivity: High metabolic activity generates reactive oxygen species, and Betz cells have limited antioxidant defenses
¶ Research Methods and Clinical Assessment
TMS is the primary non-invasive method for assessing motor cortex function and corticospinal tract integrity in clinical and research settings. Key measures include:
- Motor evoked potential (MEP) latency and amplitude — index of corticospinal conduction
- Central motor conduction time (CMCT) — delay from cortex to spinal motor [neurons[/entities/neurons
- Short-interval intracortical inhibition (SICI) — measure of GABAergic interneuron function
- Cortical silent period — reflects both cortical and spinal inhibitory processes
Abnormal TMS findings (prolonged CMCT, reduced SICI, increased cortical threshold) support the diagnosis of UMN involvement in ALS and other motor cortex disorders (Vucic et al., 2013).
- MRI: Cortical thinning in the precentral gyrus and T2 signal changes along the corticospinal tracts are visible in ALS (Agosta et al., 2012)
- Functional MRI: Altered motor cortex activation patterns in early ALS, including compensatory increases in premotor and contralateral M1 recruitment
- PET: [¹⁸F]FDG hypometabolism in the motor cortex in ALS; tau PET tracers reveal motor cortex uptake in CBD and PSP
The motor cortex is a target for several therapeutic approaches in neurodegenerative disease:
- [Riluzole[/treatments/riluzole: The first FDA-approved ALS drug, a glutamate release inhibitor that may reduce motor cortex excitotoxicity (Lacomblez et al., 1996)
- [Edaravone[/treatments/edaravone: A free radical scavenger approved for ALS that may protect motor cortex [neurons[/entities/neurons from [oxidative stress[/mechanisms/oxidative-stress
- [Tofersen[/treatments/tofersen: An [antisense oligonucleotide[/treatments/antisense-oligonucleotide-therapy targeting [SOD1[/proteins/sod1-protein, reducing mutant protein levels in both upper and lower motor [neurons[/entities/neurons
- [Deep brain stimulation[/treatments/deep-brain-stimulation of the motor thalamus for tremor in [Parkinson's disease[/diseases/parkinsons modulates motor cortex activity
- [Transcranial magnetic stimulation[/treatments/transcranial-magnetic-stimulation: Being investigated as a potential treatment for ALS by modulating motor cortex excitability
- [Stem cell therapy[/treatments/stem-cell-therapy: Motor cortex-targeted stem cell delivery is under investigation for replacing lost UMNs
This section links to atlas resources relevant to this brain region.
The study of Motor Cortex has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PubMed
- PubMed
- PubMed
- DOI
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed
- PubMed